OptimizeRx has introduced a programmatic connection between its electronic health record network and demand-side platforms, enabling life-sciences marketers to access authenticated, bot-free EHR advertising inventory directly through their existing programmatic workflows. This integration allows advertisers to activate campaigns faster, control reach and frequency independently, and embed point-of-care placements within broader omnichannel strategies.

By tapping into the broader programmatic ecosystem—responsible for nearly 90% of U.S. digital display ad spend—OptimizeRx aims to capture a share of the $19 billion pharmaceutical digital advertising market. The company’s Dynamic Audience Activation Platform is gaining traction with established and mid-tier clients, while DSP partners benefit from differentiated premium healthcare inventory.

Despite product momentum, OptimizeRx shares have fallen 29% over the past three months compared with a 4.2% rise in peer software stocks, and the stock trades at a forward 12-month price-to-sales ratio of 1.01 versus the industry’s 7.02. Investors will be watching the company’s Q1 2026 earnings report on May 12 for signs of revenue impact from the new integration and any guidance updates.